Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO ...
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain ...
AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi
AIM ImmunoTech (AIM) announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen ...